Loading…
Incyte Corporation is projected to rise to $146.58 by 2027, a +26% move from its current price of $116.71. INCY is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $114.49 | $116.75 | $119.05 | +0.03% |
| Jul 15 | $113.61 | $116.79 | $120.05 | +0.06% |
| Jul 16 | $112.94 | $116.82 | $120.84 | +0.10% |
| Jul 17 | $112.39 | $116.86 | $121.51 | +0.13% |
| Jul 18 | $111.91 | $116.90 | $122.11 | +0.16% |
| Jul 19 | $111.48 | $116.94 | $122.66 | +0.19% |
| Jul 20 | $111.10 | $116.98 | $123.17 | +0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $111.10 | $116.98 | $123.17 | +0.23% |
| Week 2 | $108.99 | $117.24 | $126.11 | +0.46% |
| Week 3 | $107.47 | $117.51 | $128.49 | +0.68% |
| Week 4 | $106.23 | $117.78 | $130.57 | +0.91% |
| Week 5 | $105.19 | $118.04 | $132.47 | +1.14% |
| Week 6 | $104.27 | $118.31 | $134.24 | +1.37% |
| Week 7 | $103.46 | $118.58 | $135.92 | +1.60% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia.
MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma.
The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progress. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors.
The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Incyte Corporation (INCY) is a Healthcare sector stock that is currently trading at $113.75. It holds a market capitalization of $22.73B and is ranked 552 in market size. The price channel and fundamentals are complemented by a multi-year forecast that suggests upside potential, with higher average prices projected beyond 2026.
The current price aligns with the near-term outlook, while the long-range forecast shows progressively higher averages through 2030, 2040, and 2050. The data indicate a path of sustained growth in the implied price, with the 2040 and 2050 figures underscoring the potential magnitude of longer-term gains.
A major floor 29.0% below — a decisive break under it would weaken the trend.
The nearest floor, 21.0% below — buyers have tended to step in here.
Price is pressing into resistance (1.6% away) — a breakout level to watch.
A major ceiling 16.0% above — clearing it would confirm fresh momentum.
Key INCY support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of INCY market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $117.23 | Sell | $116.86 | Sell |
| MA 10 | $115.86 | Buy | $114.92 | Buy |
| MA 20 | $109.90 | Buy | $111.12 | Buy |
| MA 50 | $102.82 | Buy | $105.20 | Buy |
| MA 100 | $99.42 | Buy | $101.60 | Buy |
| MA 200 | $98.73 | Buy | $96.57 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 65.01 | Neutral |
| Stoch RSI (14) | 60.67 | Neutral |
| CCI (20) | 76.17 | Neutral |
| Williams %R (14) | -12.18 | Info |
| MACD (12,26,9) | 0.59 | Buy |
| ROC (12) | 11.79 | Buy |
| Bollinger %B (20,2) | 0.76 | Neutral |
| Stochastic %K (14) | 87.82 | Sell |
| TRIX (15) | 0.58 | Buy |
| Awesome (5,34) | 11.94 | Buy |
| Ultimate (7,14,28) | 69.49 | Neutral |
| Momentum (10) | 9.18 | Buy |
| Aroon Osc (25) | 96.00 | Buy |
| Hull MA (9) | 118.47 | Sell |
| ADX (14) | 26.39 | Buy |
| ATR (14) | 1.94 | Info |
The 30-day technical picture is bullish, with RSI14 at 70. This suggests positive momentum in the near term.
The stock trades above key moving averages, with SMA50 at $99.26 and SMA200 at $97.33, while the current price sits at $113.75. This creates a constructive short-term setup against a backdrop of positive sentiment.
Over the last 30 days, the price has traded between $97.31 and $132.97, providing near-term support at $92.24 and resistance at $113.75.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $90.30 | $116.71 | $153.35 | 0% | Neutral | |
| $119.80 | $146.58 | $187.69 | +26% | Bullish | |
| $132.13 | $164.82 | $216.94 | +41% | Bullish | |
| $145.25 | $184.08 | $247.61 | +58% | Bullish | |
| $162.78 | $209.21 | $286.62 | +79% | Bullish | |
| $202.58 | $263.66 | $367.11 | +126% | Bullish | |
| $236.46 | $311.36 | $439.88 | +167% | Bullish | |
| $257.56 | $342.87 | $490.83 | +194% | Bullish | |
| $280.78 | $377.64 | $547.26 | +224% | Bullish | |
| $292.47 | $397.24 | $582.25 | +240% | Bullish | |
| $485.46 | $688.94 | $1,059.55 | +490% | Bullish | |
| $897.99 | $1,371.01 | $2,264.17 | +10.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $90.30 | $116.71 | $138.32 | +0.00% |
| August 2026 | $99.89 | $116.98 | $139.98 | +0.23% |
| September 2026 | $102.15 | $120.22 | $145.03 | +2.77% |
| October 2026 | $104.24 | $123.21 | $149.66 | +2.49% |
| November 2026 | $103.69 | $123.00 | $150.27 | -0.17% |
| December 2026 | $104.91 | $124.87 | $153.35 | +1.51% |
Click any year to see its month-by-month INCY forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The INCY price prediction for 2026 points to an average of $116.71 (low $90.30, high $153.35) — a potential gain of 0% on today's $116.71. Price action looks broadly range-bound.
In 2027, INCY is projected to trade between $119.80 and $187.69, averaging $146.58 — a potential gain of +26% from today's $116.71. That is up +26% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Incyte Corporation's 2028 outlook centres on $164.82, within a $132.13 to $216.94 range. That is up +12% on the projected 2027 average. That marks a +41% change versus current levels. Momentum favours further upside here.
By 2029, INCY could reach as high as $247.61, with a base case around $184.08 and support toward $145.25 — roughly +58% from $116.71. Buyers look set to stay in control over this stretch.
Expect INCY to range from $162.78 to $286.62 through 2030. The $209.21 average target implies a +79% move from current prices. That is up +14% on the projected 2029 average. Momentum favours further upside here.
The INCY price prediction for 2031 points to an average of $263.66 (low $202.58, high $367.11) — a potential gain of +126% on today's $116.71. Buyers look set to stay in control over this stretch.
In 2032, INCY is projected to trade between $236.46 and $439.88, averaging $311.36 — a potential gain of +167% from today's $116.71. That is up +18% on the projected 2031 average. Momentum favours further upside here.
Incyte Corporation's 2033 outlook centres on $342.87, within a $257.56 to $490.83 range. That is up +10% on the projected 2032 average. That marks a +194% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, INCY could reach as high as $547.26, with a base case around $377.64 and support toward $280.78 — roughly +224% from $116.71. Momentum favours further upside here.
Expect INCY to range from $292.47 to $582.25 through 2035. The $397.24 average target implies a +240% move from current prices. That is up +5% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The INCY price prediction for 2040 points to an average of $688.94 (low $485.46, high $1,059.55) — a potential gain of +490% on today's $116.71. Momentum favours further upside here.
In 2050, INCY is projected to trade between $897.99 and $2,264.17, averaging $1,371.01 — a potential gain of +10.7x from today's $116.71. That is up +99% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in INCY today (≈ 8.568246 INCY) could be worth
$11,747.15
+$10,747.15 (+1075%) by 2050 · US Dollar
Based on the average projected INCY price of $1,371.01 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in INCYwould be worth at today's price.
$1,000 invested in INCY on Jul 10, 2025 (≈ 14.216663 INCY) would be worth
$1,659.23
+$659.23 (+65.9%) today · 1.66× · US Dollar
Based on a INCY entry price of $70.34 vs. today's $116.71.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $116.86 | $998.72 | -0.1% |
| 1 month ago | $105.39 | $1,107.41 | +10.7% |
| 3 months ago | $96.07 | $1,214.84 | +21.5% |
| 6 months ago | $106.33 | $1,097.62 | +9.8% |
| 1 year ago | $70.34 | $1,659.23 | +65.9% |
| All time (5.0y) ago | $79.87 | $1,461.25 | +46.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our INCY forecast.
Our base-case forecast reaches $230.00 around 2031.
Implied market cap at $230.00: $45.95B
The multi-year forecast points to meaningful upside for INCY, with the 2026 min, avg, and max priced at $90.30, $113.75, and $153.84 respectively (ROI 0). By 2027, the avg rises to $141.24 with a 24.2% ROI, and by 2028 the avg is $152.96 with a 34.5% ROI. The trajectory continues through 2029 ($173.43 avg, ROI 52.5) and 2030 ($192.95 avg, ROI 69.6).
Beyond 2030, the forecast extends to 2031 ($239.38 avg, ROI 110.5), 2032 ($287.27 avg, ROI 152.5), 2033 ($308.20 avg, ROI 170.9), 2034 ($336.70 avg, ROI 196), and 2035 ($358.88 avg, ROI 215.5). The long-range view shows substantial upside, with 2040 avg $595.91 and ROI 423.9, and 2050 avg $1,185.65 with ROI 942.3. These figures reflect bullish sentiment over the horizon.
These forecasts are estimates of future prices and are not guarantees. They imply potential upside under favorable conditions but should be considered with the inherent uncertainty of long-range projections and market dynamics.
Tap a question to reveal the answer.
The 2030 forecast shows min $146.22, avg $192.95, max $273.29 with ROI 69.6% and a bullish sentiment.
The forecast shows bullish sentiment from 2027 onward, with avg prices rising from $141.24 (2027) to $192.95 (2030) and higher later, with ROIs of 24.2% (2027), 34.5% (2028), 52.5% (2029), 69.6% (2030), 423.9% (2040), and 942.3% (2050). The 2026 value is neutral with ROI 0.
Yes. The 2029 max forecast is $240.41, with the 2030 max at $273.29.
Current price: $113.75. Market capitalization: $22.73B.
30-day range is $97.31 to $132.97. Support is $92.24 and resistance is $113.75.
Incyte Corporation Community Discussion
0Share your Incyte Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.